Navigation Links
Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track
Date:11/1/2007

p>Remaining launch stocks of $28.0 million (before sales deductions) at June 2007 decreased to $14.4 million by September 30, 2007 as patients purchased LIALDA. Sales of launch stocks are being recognized into revenue as prescription demand is confirmed by IMS data. Product sales of LIALDA in the quarter totaled $16.3 million, comprising of $13.6 million of sales based on prescription demand, $6.6 million of sales from non retail demand and wholesaler restocking, net of sales deductions of $3.9 million (mainly discounts, wholesaler fees and rebates). All initial launch stocks are expected to be recognized into revenue by the end of 2007.

Since the launch of LIALDA in March 2007, PENTASA and LIALDA's combined share of the US oral mesalamine prescription market had grown to 23% by September 30, 2007, up from 18% at September 30, 2006.

FOSRENOL - Hyperphosphatemia

FOSRENOL has now been launched in 23 countries and global sales totaled $28.7 million for the quarter ended September 30, 2007 (2006: $12.2 million). In Europe, FOSRENOL has been launched in Germany, France, UK, Italy and a number of other countries; launches will continue throughout 2008, including in Spain, subject to finalization of national marketing authorizations and the conclusion of pricing and reimbursement negotiations. European sales of FOSRENOL for the three months to September 30, 2007 were $12.4 million, up 38% compared with Q2 2007 ($9.0 million).

US sales of FOSRENOL for the three months to September 30, 2007 were up 43% to $16.3 million compared to the same period in 2006 (2006: $11.4 million). FOSRENOL's average market share of the US phosphate binder market remained constant at 9%. The increase in product sales is due to the uptake in higher strength doses of FOSRENOL and wholesaler de-stocking of initial launch stocks in Q3 2006.

CARBATROL - Epilepsy

US prescriptions for CARBATROL for the three months ending September 30, 2007 were down 5% compared to th
'/>"/>

SOURCE Shire plc
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related medicine news :

1. Further support for use of statins in Alzheimer’s disease
2. Clinical Impact of Activity and Abdominal Pressure on Pelvic Floor Dysfunction Need to Be Further Analyzed
3. Doctor Accused Of Misdiagnosing 208 Patients: Further Investigation Ordered
4. NHS announces further Cost cutting Measures
5. NHS Recommends Further Cost Cutting Measures
6. Medha Patkars Condition Deteriorates Further
7. Oxford Radcliffe Hospitals Warns Of Further Job Losses
8. Asia Arming up to further the AIDS fight
9. Further Studies Needed To Completely Understand About Ventricular Fibrillation
10. Further improvements envisaged at Carstairs
11. UCLA Find Yields Further Insight into Causes of Parkinson’s Diseas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2015)... ... , ... Natural Rest contains a unique mixture of vitamins and herbs that ... help to improve mood disorders and anxiety. Like all other Creative Medical Health products, ... of regenerative medicine conducted by Dr. Amit Patel of the University of Utah, one ...
(Date:8/30/2015)... Boca Raton, Fl (PRWEB) , ... August 30, ... ... today that Executive Vice President Jeff Fernandez will lead the expansion of global ... of cosmeceutical and skin care experience having spent the last 25 years working ...
(Date:8/30/2015)... ... August 30, 2015 , ... SonaCare Medical, LLC, ... treatment of prostate cancer, has announced the roll-out of its newest technology – ... in Puerto Vallarta, Mexico. , The Sonablate® technology currently in use at the ...
(Date:8/29/2015)... ... ... On September 30, 2015, the Career and Transfer Center (CTC) at Estrella ... Colleges , will be hosting a Job Expo to provide a professional, open venue ... Expo has expanded to much more than just a typical job and career fair. ...
(Date:8/29/2015)... ... August 29, 2015 , ... On Saturday, September 19, ... Applied Research Foundation (Meso Foundation) will present an educational program titled “Asbestos and ... and lasts through 9:30 PM (doors open at 6:45pm) at Calvary United Methodist Church, ...
Breaking Medicine News(10 mins):Health News:Creative Medical Health’s Natural Rest® Now Available on ReCreative Medical Health’s Natural Rest® Now Available on RevNutrition.com 2Health News:NPI Executive Vice President Leads Cosmeceutical Expansion 2Health News:Image Fusion Technology Combines MRI and Ultrasound Images to Treat Prostate Cancer 2Health News:Estrella Mountain Community College Expo Offers ‘One-Stop’ for Employers and Students Seeking Internships, Jobs, Careers and Service Learning Opportunities 2Health News:Mesothelioma Applied Research Foundation to Hold Educational Class About Asbestos and Mesothelioma Prevention 2
... validity of Purdue patents; Receives limited license rights ... ST. LOUIS, June 9 KV Pharmaceutical Company (NYSE: ... it has entered into a settlement agreement with Purdue Pharma ... lawsuit between the two companies. Under the terms of ...
... early in the course of disease is the best approach ... acute myeloid leukemia (AML), according to a new analysis of ... published in the June 10 issue of the Journal ... Cancer Institute and other institutions, provide new guidelines for treatment ...
... , WASHINGTON, June 9 The "Blue Dog Coalition," a ... oppose a strong public option to for-profit health insurers, took ... insurance and drug industries according to Consumer Watchdog. , ... Landrieu (D-LA) now opposes the public option. Landrieu received ...
... expert says, , TUESDAY, June 9 (HealthDay News) -- ... women as their pregnancy progresses, a new Brazilian study ... to 80 percent of moms-to-be suffering heartburn, stomach pain ... worsen over time, and women who avoid taking medicine ...
... PEMBROKE, Bermuda, June 9 Allied World Assurance,Company (U.S.) ... Ltd (NYSE: AWH ), today announced an ... in the United States. The,complimentary service, called "Strategic Response(SM)," ... resources in the,event of a catastrophe. , ...
... New Dialysis Patients Making a Difference in Cutting Patient Mortality ... (NYSE: DVA ), a leading provider of kidney ... today commended Kidney Care Partners for launching the Performance Excellence ... Partners - a coalition of patient advocates, dialysis professionals, care ...
Cached Medicine News:Health News:KV Pharmaceutical Company, Purdue Pharma L.P. Settle OxyContin(R) Dispute 2Health News:KV Pharmaceutical Company, Purdue Pharma L.P. Settle OxyContin(R) Dispute 3Health News:KV Pharmaceutical Company, Purdue Pharma L.P. Settle OxyContin(R) Dispute 4Health News:KV Pharmaceutical Company, Purdue Pharma L.P. Settle OxyContin(R) Dispute 5Health News:KV Pharmaceutical Company, Purdue Pharma L.P. Settle OxyContin(R) Dispute 6Health News:Study IDs benefit of donor SCT for adults with acute myeloid leukemia 2Health News:Will Insurer & Drug Money Leash the 'Blue Dogs'? 2Health News:Will Insurer & Drug Money Leash the 'Blue Dogs'? 3Health News:Will Insurer & Drug Money Leash the 'Blue Dogs'? 4Health News: Acupuncture May Relieve Heartburn In Pregnancy 2Health News: Acupuncture May Relieve Heartburn In Pregnancy 3Health News:Allied World U.S. Announces Strategic Response(SM) - Complimentary Service Added to General Liability Lead Umbrella Product 2Health News:Allied World U.S. Announces Strategic Response(SM) - Complimentary Service Added to General Liability Lead Umbrella Product 3Health News:DaVita Commends Kidney Care Partners for Launch of PEAK Campaign 2Health News:DaVita Commends Kidney Care Partners for Launch of PEAK Campaign 3
(Date:8/28/2015)... Aug. 28, 2015 Research ... of the "Investigation Report on China,s Ranibizumab Market, ... by Novartis, ranibizumab was approved by CFDA to treat ... only Lucentis, a product of Novartis, is available in ... first self- developed drug for the treatment of wet ...
(Date:8/28/2015)... , Aug. 28, 2015  Perrigo Company plc ... it has completed the acquisition of leading OTC brands ... €200 million. The transaction is a clear demonstration of ... Company,s leading European distribution network spanning 36 countries.  ... C. Papa commented, "We are excited to complete ...
(Date:8/28/2015)... PUNE, India , August 28, 2015 ... Essential Oils), Livestock (Pork/Swine, Poultry, Ruminant, and Aquaculture), & by ... , Asia-Pacific , and Rest of ... by MarketsandMarkets, The global market for Eubiotics was valued at ... USD 7.05 Billion by 2020, at a CAGR of 7.4% ...
Breaking Medicine Technology:Investigation Report on China's Ranibizumab Market, 2012-2019 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4Eubiotics Market Worth 7.05 Billion USD by 2020 2Eubiotics Market Worth 7.05 Billion USD by 2020 3Eubiotics Market Worth 7.05 Billion USD by 2020 4Eubiotics Market Worth 7.05 Billion USD by 2020 5
Angled shafts with 12 mm scaled jaws. 1 mm teeth on one jaw fit into holes on the other jaw. Slide lock and serrated handle with polished finish. Right. Most popular size or model....
Angled 13.5 mm adjustable blades. Teeth in lower jaws fit into holes in upper jaws. Grooves in lower jaw for passage of suture needles. Round knurled handle with polished finish....
Straight shafts with 5.5 mm tying platform and 1 mm crisscross serrated tips. Wide serrated handle with polished finish....
Delicate # 4...
Medicine Products: